Twitter Rx Drug Promos: FDA Studies Best Way To Convey Risk Info
Executive Summary
Agency to assess whether individuals have greater retention of risk information if it is included directly in online communications with limited character space rather than via a link.
You may also be interested in...
Rx Drug Promotion: Inclusion Of Extensive Risk Info In Twitter, Google Ads Has Potential Drawback
US FDA study of character-space-limited prescription drug communications finds consumers may be less likely to click on a link for more risk information if the promo already has substantial details.
Twitter Promo Study Gets Tweaks, But FDA Rejects Many Industry Suggestions
Lilly recommended testing use of embedded Twitter cards to convey safety information and PhRMA proposed studying a universal graphic symbol or FDA's logo.
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.